1 in 4 teens are forced to leave home after coming out.
Many ppl under 26 are on their parents' health insurance, making coming out even scarier than it already is bc it might mean that you need to find new insurance fast- not easy & $ in the USA (3/11)
If you really want to earn the 🏳️🌈on your twitter banner, commit to not enforcing patents in LMICs, lowering prices in HICs, & ensuring robust access plans for those w/o insurance (6/11)
.@abbvie: No specific asks here, just want to encourage folks to read the '21 House Cmte on Oversight + Reform report (excerpts below)
tldr: Questionably legal practices-> $19bn costs to US healthcare
.@GileadSciences: Your portfolio includes a significant number of drugs essential for treating HIV and HCV, diseases the disproportionately affect LGBTQ+ people.
It's wild and bad that Biontech tried to get public mentions of #CTAP, a @WHO housed initiative to pool intellectual property, scrapped as "vaccine misinformation".
This is not the pharma's first bizarre anti-generics campaign. A quick bit of history.🧵1/
9 months later, no real news.
❌generic supply is still not widely available
❌Pfizer is refusing to expand licensing
🥴no trial data on how it works in key populations
Here's the top-line summary, using current prices of API traded in global markets.
#Paxlovid is $530 in the US. It has been reported that in China right now, desperate people have been paying as much as $7,000 to get it for their loved ones. 2/ reuters.com/business/healt…
Cost-based estimated generic prices use the price of active pharmaceutical ingredient (API) traded in global markets, and a cost estimation algorithm we developed in earlier research (see gh.bmj.com/content/3/1/e0…)
Costs come down exponentially when there is competition, but.. 3/
I saw videos I posted retweeted out of context, so I want to be clear abt a few things.
What has happened this week is pharma's failure to show up & be transparent abt contracts and pricing has fanned the flames of of distrust about vax effectiveness.
I encourage folks to read the linked tweet (above) on the transmission q.
I really wish MEPs had the opportunity to pose questions to someone who had been involved in the R&D side of things rather than the business side of things so their questions could have been answered. 2/5
BUT I want to correct the record bc some news has reported on the committee meeting as if it were entirely abt that, when in fact most MEPs were focused on concerns abt democratic process: public money shd be accounted for in transparent contracts. 3/5
1) member states are furious by the lack of transparency & #SMSgate 2) @AlbertBourla miscalculated that this was something he could skip. 3) The committee is ready to recommend consequences
Summary in 🧵1/
I don't usually do full 🧵 detailing hearings (apologies in advance), but what happened yesterday was pretty extraordinary and I think will be important in setting the course for ongoing future pandemic planning.
"I must say that it is a disgrace that @AlbertBourla is not with us today and an even greater disgrace that he doesn't have any real intention of showing up." 3/
"The sheer complexity of insulin production makes it financially unviable for generic companies. Thus, instead of generic insulin, we speak of biosimilar insulin — a biosimilar is a biologic drug that is extremely similar but not identical to the original." 2
First, generic insulin markets are 100% financially viable. I hate to be that academic that says "I have a paper on that" but gh.bmj.com/content/3/5/e0…
We assume a 10% profit margin (which is more than average) & estimate costs at ~$3/vial for NPH + $5 for glargine. V. viable! 3